Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
9
×
boston blog main
fda
9
×
life sciences
national blog main
boston top stories
clinical trials
biotech
national top stories
alnylam pharmaceuticals
deals
patisiran
drugs
hereditary transthyretin amyloidosis
new york blog main
new york top stories
onpattro
rna interference
san diego blog main
san diego top stories
san francisco blog main
akcea therapeutics
alexion pharmaceuticals
european medicines agency
inotersen
investing
pfizer
rare disease drugs
roche
san francisco top stories
tafamidis
acute hepatic porphyrias
akin akinc
akouos
allopregnanolone
aminolevulinic acid
amyotrophic lateral sclerosis (als)
andrew fire
astellas pharmaceuticals
autoimmune disorders
What
drug
9
×
fda
medicines
medicine
pharmaceuticals
alnylam
approved
rnai
approval
candidate
developing
disease
gene
interference
ipo
muscle
pharma
protein
rna
roche
specifically
team
therapeutics
affects
afternoon
ago
alnylam’s
alternative
americans
approves
autoimmune
blueprint
brexanolone
brings
cancer
caught
causing
cells
company
currently
Language
unset
Current search:
fda
×
drug
×
boston
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug